Dimension Bio CEO Caralynn Nowinski Collens, M.D., discusses the company's mission to create life-saving regenerative therapies, particularly for liver disease. She shares her journey in the startup world, the increasing demand for liver treatments, and the innovative approaches Dimension Bio is taking with cell-based therapies. The conversation also touches on recent advancements, regulatory challenges, and future predictions for the field of regenerative medicine.

Chapters

00:00 Introduction to Dimension Bio and Its Mission

02:39 Caralynn's Journey and Leadership in Startups

05:13 The Growing Need for Liver Disease Treatments

08:23 Understanding Cell-Based Therapies

11:15 Recent Milestones and Innovations in Therapy

14:03 The Mechanism of Action and Placement of Therapies

16:59 Regulatory Landscape and Future Predictions

19:40 Final Thoughts and Future Aspirations